Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HepG2 cell line

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Sun, Jianguo ^a,b   Yeung, Chilam Au ^b   Co, Ngai Na ^b   Tsang, Tsun Yee ^b   Yau, Esmond ^b   Luo, Kewang ^a,b   Wu, Ping ^a,b   Wa, Judy Chan Yuet ^b   Fung, Kwok Pui ^b   Kwok, Tim Tak ^b   Liu, Feiyan ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLITOCINE; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOSIDE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; LIVER CELL CARCINOMA; MOUSE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE 1 GENE; NONHUMAN; PROMOTER REGION; STOMACH CANCER; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; UTERUS CARCINOMA;

EID: 84865192351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040720     Document Type: Article

References (48)

1. Gottesman MM, Pastan I, (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
3. Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR, (1983) Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67: 869-874.
4. Bosch I, Croop J, (1996) P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37-54.
5. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
6. Hennessy M, Spiers JP, (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55: 1-15.
7. Krishna R, Mayer LD, (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283.
8. Yusa K, Tsuruo T, (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49: 5002-5006.
9. Loo TW, Clarke DM, (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem 276: 14972-14979.
10. Slater L, Sweet P, Wetzel M, Stupecky M, Osann K, (1995) Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 19: 543-548.
11. Chin KV, Ueda K, Pastan I, Gottesman MM, (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462.
12. Cornwell MM, Smith DE, (1993) SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268: 19505-19511.
13. Zhou G, Kuo MT, (1998) Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem 273: 15387-15394.
14. Zhou G, Kuo MT, (1997) NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 272: 15174-15183.
15. Fine RL, Chambers TC, Sachs CW, (1996) P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 14: 47-55.
16. Tang XY, Zhu YQ, (2008) Epigallocatechin-3-gallate suppressed the over-expression of HSP 70 and MDR1 induced by heat shock in SGC 7901. J Chemother 20: 355-360.
17. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM, (1990) Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265: 221-226.
18. Fujita T, Ito K, Izumi H, Kimura M, Sano M, et al. (2005) Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11: 8837-8844.
19. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, et al. (2004) MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther 3: 540-548.
20. Yatouji S, El-Khoury V, Trentesaux C, Trussardi-Regnier A, Benabid R, et al. (2007) Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and-resistant OV1 cell lines. Int J Oncol 30: 1003-1009.
21. Kim SN, Kim NH, Lee W, Seo DW, Kim YK, (2009) Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res 7: 735-744.
22. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, et al. (2005) Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 28: 823-828.
23. Mothana RA, Lindequist U, Gruenert R, Bednarski PJ, (2009) Studies of the in vitro anticancer, antimicrobial and antioxidant potentials of selected Yemeni medicinal plants from the island Soqotra. BMC Complement Altern Med 9: 7.
24. Patanasethanont D, Nagai J, Matsuura C, Fukui K, Sutthanut K, et al. (2007) Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur J Pharmacol 566: 67-74.
25. Moss RJ, Petrie CR, Meyer RB Jr, Nord LD, Willis RC, et al. (1988) Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside. J Med Chem 31: 786-790.
26. Lee CH, Daanen JF, Jiang M, Yu H, Kohlhaas KL, et al. (2001) Synthesis and biological evaluation of clitocine analogues as adenosine kinase inhibitors. Bioorg Med Chem Lett 11: 2419-2422.
27. Fortin H, Tomasi S, Delcros JG, Bansard JY, Boustie J, (2006) In vivo antitumor activity of clitocine, an exocyclic amino nucleoside isolated from Lepista inversa. ChemMedChem 1: 189-196.
28. Ren G, Zhao YP, Yang L, Fu CX, (2008) Anti-proliferative effect of clitocine from the mushroom Leucopaxillus giganteus on human cervical cancer HeLa cells by inducing apoptosis. Cancer Lett 262: 190-200.
29. Liu F, Hu X, Zimmerman M, Waller JL, Wu P, et al. (2011) TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One 6: e16241.
30. Tang PM, Chan JY, Zhang DM, Au SW, Fong WP, et al. (2007) Pheophorbide a, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. Cancer Biol Ther 6: 504-509.
31. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
32. Karin M, Lin A, (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
33. Pahl HL, (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
34. Ueda K, Pastan I, Gottesman MM, (1987) Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 262: 17432-17436.
35. Karin M, (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18: 6867-6874.
36. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M, (1995) Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis. Science 270: 286-290.
37. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M, (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388: 548-554.
38. Chu ZL, Shin YA, Yang JM, DiDonato JA, Ballard DW, (1999) IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1. J Biol Chem 274: 15297-15300.
39. Israel A, (2010) The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2: a000158.
40. Wang CY, Mayo MW, Baldwin AS Jr, (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787.
41. Aydin C, Sanlioglu AD, Bisgin A, Yoldas B, Dertsiz L, et al. (2010) NF-kappaB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer 10: 584.
42. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr, (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417.
43. Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, et al. (2007) Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One 2: e1313.
44. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, et al. (1999) Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 59: 811-815.
45. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, et al. (1998) DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1: 543-551.
46. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, et al. (2002) Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21: 1945-1954.
47. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, et al. (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97.
48. Nakanishi C, Toi M, (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.